Alcobra (ADHD) To Provide Corporate Overview At The JMP Securities Healthcare Conference
6/17/2014 8:46:38 AM
TEL AVIV, Israel, June 17, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the JMP Securities Healthcare Conference, taking place June 24-25 in New York City.
Help employers find you! Check out all the jobs and post your resume.
comments powered by